Immunotherapy has transformed cancer treatment by harnessing the immune system to attack tumors. Patients with ARID1A gene mutations show increased response to immunotherapy, particularly immune checkpoint blockade. The mutation triggers an antiviral immune response that attracts cancer-fighting immune cells into the tumor, enhancing the effectiveness of treatment. Understanding this mechanism could lead to better patient selection for immunotherapies and the development of drugs targeting ARID1A to sensitize tumors to treatment. By elucidating the relationship between ARID1A mutations and immunotherapy response, researchers aim to personalize cancer treatment and improve outcomes for patients with various ARID1A-associated cancers.
Source link
Enhancing patient response to cancer immunotherapy
